



science and policy
for a healthy future

Berlin, 09 November 2017

Draft Minutes (11/2017)

TOPIC meeting in connection to 8th HBM4EU Management Board Meeting

Thursday, 09 November 2017, from 13:00 to 18:00 o'clock

Venue: Room No. 1042, Bismarckplatz 1, 14193 Berlin,

Agenda:

Time	Item No.	Topic
13:00 – 15:00	1	Content Discussion (Greet Schoeters) Welcome and Organisational Issues Topic 1: Connecting between pillars and WPs: the example of bisphenols All WPs are asked to introduce their activities on bisphenols by max 2 slides
15:00 - 15:30		<i>Coffee Break</i>
15:30 – 17:00	2	Topic 2 Making data available for HBM4EU Experiences Obstacles Solutions

Goals of the meeting:

- Identify gaps in WP activities to answer policy questions
- Identify connections – within and between WPs- that are needed to improve efficiency
- Identify overlaps in activities
- Propose solutions

The presentations are available to download from the internal webpages.

Main conclusions and actions:	WP
<p>Policy questions presented in AWP and scoping documents are not the same.</p> <p>Scoping documents should include all questions that come from all stakeholders. AWP filters out these questions on which activities will be developed in the upcoming year. WP4.1 keeps a list of policy- and stakeholder needs as a living document (Catherine).</p>	4
<p>Current categorisation of bisphenols is still under discussion. The analytical methods for bisphenol S and F are not ready. According to the new definitions they should be shifted from category B to category C. Categorisation of substances still need to be put in practice and may be fine-tuned. Also input from experience on categorization of CGLs is expected (action WP4).</p>	4
<p>Bisphenols will be proposed to the policy board as a case study to be taken up at EU level (WP5.5)</p>	5
<p>Deliverable 5.1 on risk assessment (RA) contains state of the art information on RA of the priority substances. It will be disseminated after incorporating the last editorial comments. Since the deliverables will be published on the web site, they should be of sufficient quality according to the standard we want to set in HBM4EU</p>	5
<p>Questionnaire on BPA is almost finalized as well as the questionnaires for the other specific substances and can be soon made available to the new studies. The questions are based on questionnaires from experienced partners and relate to BPA.</p> <p>The analysis of exposure determinants can be complemented with GIS based information (WP12).</p> <p>WP12 will provide input for the short questionnaire that will be used to document the individual behaviour and residency just before sampling. The WP12 input is based on the information that came out of the toxicokinetic modelling and that is needed to validate the models.</p> <p>WP12 recommends to use morning spot urine samples for short lived compounds such as bisphenols. They are able to reconstruct exposures of the previous day based on these morning spot urine samples. Close interaction between WP12 and WP7-WP8 for study design, questionnaires and protocol development (Spyros/Dennis- Ulrike, Ovnair, Greet).</p>	7, 8 and 12
<p>There is an initial list of studies dealing with bisphenols. WP10 partners will bring the data together, transfer to repository and IPCHEM , statistical analysis are expected to be started in 2018. Bottle necks are the ethical permissions, the ethical approvals and data protection documentation, consolidation of the information provided in Q7.1 with each study center.</p> <p>The provisional list of planned and ongoing studies in EU is limited and we have less data and studies than expected. Only data of BPA. No information retrieved from BPS and BPF.</p>	8 and 10
<p>A major concern is compatibility of the available data. For bisphenols there is:</p> <ul style="list-style-type: none"> ➤ concern for background contamination if BPA is measured after deglucuronidation. More precise methods for measuring specific metabolites (e.g. glucuronide and sulphate conjugates) would be helpful. ➤ Different labs used different data processing methods that need to be checked (harmonization of procedures for (1) characterizing and (2) take into account the background contamination level in the reported results) 	8 and 9, 16

<p>Policy makers expressed interest in bisphenol exposure of cashiers and evaluation of the effectiveness of policy measures. It has to be checked how relevant this still is, given the change in regulation that is expected to be implemented from 2020 on. Advice will be asked from the EU policy board (Catherine), Tiina Santonen, ANSES (Robert) →information for WP8 (Ovnair).</p>	8
<p>Inter-laboratory comparisons for performance of analytical methods will be initiated . It will not be possible to organise these QAQC for all nominated chemicals in a substance group. The most important chemicals will be selected. T. Goen will organize these QAQC exercises. For BPA this will permit to check/confirm the performances of existing methods already in place in several labs. For BPF and BPS this will permit to consolidate the performances of the few existing methods and to identify some optimization points to be considered for better harmonization between the different labs.</p>	9 and 16
<p>For BPA toxicokinetic models are well developed and can be applied. They will be applied on HBM samples collected in the survey, for BPS and BPF only QSARS may give some information. WP12 indicates the importance to collect information on exposure route (dermal, inhalation, oral) since it will influence the kinetics of the bisphenols. Age is important as glucuronidation changes with age. We can anticipate that genetic polymorphisms play a role as well. Not yet included in HBM4EU sampling and analysis.</p>	12
<p>Different approaches are taken to include mechanistic information and relate it to the exposure markers. This needs to be further elaborated and more exchange is needed. AOP information (WP13) will need to link to effect biomarkers (WP14). Effect biomarkers (WP14) will need to be linked to exposure biomarkers (WP8/9/16).</p>	13 and 14
<p>Literature review is performed in various WPs and tasks. We should prevent overlap!</p> <ul style="list-style-type: none"> ➤ Background documents (WP4) ➤ Scoping documents (WP4) ➤ A detailed and thorough assessment of the available biomonitoring and exposure data literature (WP7) ➤ Biomarkers and analytical techniques (WP9) ➤ Text mining (Barouki- WP13) ➤ AOPs (WP13) ➤ Pubmed analysis based on MESH terms (WP14) <p>Action: to make a matrix and indicate for each WP who is working on a specific substance. This information needs to be provided to the CGLs.</p> <p>Next to information from the open literature, there is also recent valuable information coming from eg the exposome projects. Marike will ask the EC officer how HBM4EU may connect to these projects and build further on the yet unpublished information.</p>	4, 9, 13, 14
<p>WP leaders have to evaluate the time line of their activities and deliverables and check whether they allow timely integration of activities across WPs.</p>	all
<p>Flame retardants (FRs) and PFASs may be important topics to discuss next time. The CGL needs to be present. Ludek will check with Jana for the FRs.</p> <p>Other suggestions for topics:</p> <ul style="list-style-type: none"> ➤ data structure (Erik) ➤ AOPs and effect markers and linkage to exposure markers of surveys ➤ Risk assessment (WP5) 	13 and all

TOPIC data availability:

This discussion was short but emphasised the need for working closely together

10,
11,12,
15

WP10- WP11: skype conference to be organised (action Greet)

WP12: what is needed in terms of HBM population data and accessory data? Spyros makes a list of data needed and provides it to WP10

WP15: collaboration with WP10 needs to be planned regularly

Attendees: 09.11.2017

WP	Partner	First Name	Name
01	UBA	Marike	Kolossa-Gehring
02, 04	EEA	Catherine	Ganzleben
05, 10	VITO	Greet	Schoeters
06	INSERM	Robert	Barouki
07	UBA	Ulrike	Fiddicke
08	DH	Ovnair	Sepai
09	ISCI	Argelia	Castaño
11	THL	Hanna	Tolonen,
12	AUTH	Spyros	Karakysios
13	MU	Ludek	Blaha
14	UGR	Nicolas	Olea
15	RIVM	Erik	Lebret
16	INRA	Jean-Philippe	Antignac (video connection)
	ISCI	Marta	Esteban
	EEA	Joana	Lobo Vicente
	UBA	Ulrike	Doyle
	INSERM	Elena	Tarroja